• About
  • Alzosure Test
  • Alzosure Predict
  • Literature
  • Publications
  • Board of Directors
  • Team
  • MAB
  • Partners
  • News
  • Diadem US Inc
  • About
  • Alzosure Test
  • Alzosure Predict
  • Literature
  • Publications
  • Board of Directors
  • Team
  • MAB
  • Partners
  • News
  • Diadem US Inc

Diadem Receives CE-IVD Certification to Market Its AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease in Europe

by Claire | Oct 23, 2022 | Uncategorized

DIADEM RECEIVES CE-IVD CERTIFICATION TO MARKET ITS ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR THE EARLY PREDICTION OF ALZHEIMER’S DISEASE IN EUROPE —First Approved Blood Test that Can Predict Likely Progression to Alzheimer’s Disease Up to Six Years in Advance—...

Presentation at Clinical Trials on Alzheimer’s Disease Meeting Highlights How Diadem’s AlzoSure® Predict Can Enable AD Clinical Trials and Screening for Early Detection of AD

by Claire | Oct 23, 2022 | Uncategorized

PRESENTATION AT CLINICAL TRIALS ON ALZHEIMER’S DISEASE MEETING HIGHLIGHTS HOW DIADEM’S ALZOSURE® PREDICT CAN ENABLE AD CLINICAL TRIALS AND SCREENING FOR EARLY DETECTION OF AD —Longitudinal Analyses Show AlzoSure® Predict Identifies Individuals Who Will Progress to...

FDA Grants Breakthrough Device Designation to Diadem’s AlzoSure® Predict Prognostic Blood Test for the Early Prediction of Alzheimer’s Disease

by Claire | Oct 23, 2022 | Uncategorized

FDA GRANTS BREAKTHROUGH DEVICE DESIGNATION TO DIADEM’S ALZOSURE® PREDICT PROGNOSTIC BLOOD TEST FOR THE EARLY PREDICTION OF ALZHEIMER’S DISEASE —First Prognostic Blood Test that Can Predict Likely Progression to Alzheimer’s Disease Up to Six Years in Advance—  ...

DIADEM PRESENTS DATA AT AD/PD™ 2022 INTERNATIONAL CONFERENCE DEMONSTRATING ITS NEW ALZOSURE® CONFIRM BLOOD TEST HAS THE POTENTIAL TO ACCURATELY DIAGNOSE ALZHEIMER’S DISEASE

by Claire | Oct 23, 2022 | Uncategorized

DIADEM PRESENTS DATA AT AD/PD™ 2022 INTERNATIONAL CONFERENCE DEMONSTRATING ITS NEW ALZOSURE® CONFIRM BLOOD TEST HAS THE POTENTIAL TO ACCURATELY DIAGNOSE ALZHEIMER’S DISEASE —Have Identified Specific Post Translational Modifications of a Conformational Variant of p53...

Diadem Announces New Publication Reviewing How Post Translational Modifications of p53 Variants May Contribute to Development of Alzheimer’s Disease

by Claire | Oct 23, 2022 | Uncategorized

DIADEM ANNOUNCES PUBLICATION OF PEER-REVIEWED ARTICLE DESCRIBING HOW POST-TRANSLATIONAL MODIFICATIONS OF P53 VARIANTS MAY CONTRIBUTE TO DEVELOPMENT OF ALZHEIMER’S DISEASE —Post-Translational Modifications of Conformational Variants of p53 Appear to Impact Pathogenesis...
« Older Entries
Next Entries »

Recent Posts

  • Diadem and the University of Texas Medical Branch report new evidence on Alzheimer’s biomarker at CTAD 2026
  • Diadem awarded US patent for AlzoSure® Alzheimer’s disease prediction technology
  • Seed Healthcare Leads Strategic Investment in Diadem
  • Diadem Unveils Novel Findings on Early Alzheimer’s Disease Detection Using p53-Specific Antibody at CTAD 2024
  • Diadem Appoints Michael Rasche as Chief Executive Officer

Recent Comments

No comments to show.

Blood-based diagnostics for early detection of Alzheimer’s disease

Legal Headquarters:
Diadem S.p.A.
Via Ceresio 7
Milano, Italy

Diadem US, Inc
1117 S.California Avenue
Palo Alto , CA94304

Diadem GmbH
Faberstrasse 8D
81373 München, Germany

Email: execadmin@diademdx.com

Diadem tests are not approved under any geography

SITE MAP

  • Home
  • About
  • AlzoSure Test
  • AlzoSure Predict
  • Literature
  • Publications
  • Board of Directors
  • Team
  • MAB
  • Partners
  • News
  • Diadem US Inc

Copyright © 2026 All Rights Reserved by Diadem S.p.A.  |  Privacy Policy  |  Cookie Policy